It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What ...

PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solu ...

It has been about a month since the last earnings report for IQVIA Holdings (IQV) . Shares have added about 3.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. IQVIA Surpasses Q2 Earnings Estimates IQVIA Holdin ...

I I F ■ F Matteo Colombo Investment update Following my May publication on IQVIA Holdings Inc. (NYSE:IQV) the stock is +5%, marking a 28% return since I first rated the business investment-grade back in Jan '21. This is a business I know tremendously well, having analyzed its credentials for more than 3 years and owned the stock for our equity budget for that entire duration. In the five publications I've made on IQV here on SA since then, my views have not changed on this long-term compounder. Following it ...

Core Insights - IQVIA Holdings Inc. (IQV) shares have increased by 12% over the past year, outperforming the industry growth of 10% [1] - The company has a projected long-term EPS growth rate of 10.4%, with anticipated earnings growth of 9.5% for 2024 and 11% for 2025 [1] Financial Performance - The Technology & Analytics Solutions (TAS) segment saw a 4% revenue increase in Q2 2024, excluding COVID-19 impacts and foreign exchange effects, with expected TAS revenue growth of 6-7% for the second half of the year [2] - R&D Solutions (R&DS) recorded new bookings of approximately $2.7 billion and a record backlog of $30.6 billion, indicating strong future revenue potential [3] - Management expects total revenues for Q3 2024 to be between $3.83 billion and $3.88 billion, and for full-year 2024 to be in the range of $15.4 billion to $15.5 billion [4] - EPS for Q3 2024 is anticipated to range between $2.76 and $2.86 per share [4] Strategic Initiatives - The company is investing in AI and machine learning, leading to market-leading solutions that enhance operational efficiency and client engagement [5] - In Q2 2024, IQVIA contracted with a top 20 client to expand its commercial technology ecosystem, integrating AI and ML offerings into the client's infrastructure for better data management [6] Operational Challenges - The company faces challenges due to large pharmaceutical companies implementing cost-cutting measures, affecting pricing negotiations in both commercial and R&DS segments [6] - Operating expenses increased to $509 million in Q2 2024 from $482 million in Q2 2023, indicating rising costs [7] - The current ratio was 0.84 at the end of Q2 2024, suggesting potential difficulties in meeting short-term obligations [8]

In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a company's dependence on overseas markets, as this offers a window into the company's earnings stability, its ability to benefit from varied economic cycles and its potential for long-term growth. Participation in global economies acts as a defense against economic difficulties at home and a pathway ...

Core Viewpoint - Investors are evaluating IQVIA Holdings (IQV) and Waters (WAT) for potential undervalued stock opportunities, with IQV currently appearing as the more favorable option based on various valuation metrics [1]. Valuation Metrics - IQV has a forward P/E ratio of 22.16, while WAT has a higher forward P/E of 25.97, indicating that IQV may be more attractively priced [3]. - The PEG ratio for IQV is 2.05, compared to WAT's PEG ratio of 4.90, suggesting that IQV's expected earnings growth is more reasonably priced [3]. - IQV holds a Value grade of B, while WAT has a Value grade of D, reflecting stronger estimate revision activity and more attractive valuation metrics for IQV [4]. Zacks Rank and Style Scores - IQV has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while WAT has a Zacks Rank of 4 (Sell) [2]. - The Zacks Rank system favors stocks with strong earnings estimate revisions, and combining this with a strong Value grade can help identify great value stocks [5]. Additional Valuation Comparisons - IQV's P/B ratio is 6.65, significantly lower than WAT's P/B ratio of 14.50, further indicating that IQV may be undervalued relative to its book value [6]. - The Value category of the Style Scores system utilizes various metrics, including P/E ratio, P/S ratio, earnings yield, and cash flow per share, to assess a company's fair value [7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35907 _____________________________________________________ ...

Life sciences clinical researcher IQVIA's second-quarter results beat analysts' expectations for revenue and net income. The company also raised its full-year guidance. IQVIA said its technology and analytics products were major growth drivers. IQVIA's stock rose nearly 7% in intraday trading Monday to move into positive territory for the year. Growth Driven by Technology & Analytics Solutions Unit Looking ahead, IQVIA narrowed its full-year revenue guidance to a range of $15.43 billion to $15.53 billion fr ...